{"id":"W2132940815","doi":"10.1093/annonc/mdl355","title":"Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study","year":2006,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":false,"ca_institutions":"Collège Montmorency","funders":"Sanofi; Amgen","keywords":"Medicine; Epirubicin; Docetaxel; Regimen; Internal medicine; Cyclophosphamide; Gastroenterology; Febrile neutropenia; Anthracycline; Breast cancer; Neutropenia; Chemotherapy regimen; Taxane; Chemotherapy; Oncology; Surgery; Urology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001060054,0.001152181,0.001828682,0.0004554865,0.0002909049,0.0005547556,0.0009906249,0.001049431,0.004682987],"category_scores_gemma":[0.0007950774,0.0003842146,0.001112603,0.0005204803,0.0007141492,0.0004197305,0.0002339435,0.001873468,0.0007219397],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008029569,"about_ca_system_score_gemma":0.001137016,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002890587,"about_ca_topic_score_gemma":0.006897136,"domain_scores_codex":[0.9997156,0.0001617712,0.00001602236,0.00003427188,0.00001980597,0.00005253761],"domain_scores_gemma":[0.9993464,0.0001794488,0.0001383875,0.00005436052,0.00002353158,0.0002577317],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9627083,0.009483117,0.0006390777,0.000373144,0.0004094935,0.00003233722,0.00003183345,0.0004887832,0.005388569,0.0001175999,0.0008364568,0.0194912],"study_design_scores_gemma":[0.8768862,0.1163598,0.0040151,0.00004375464,0.000430181,0.0000613933,0.00002000175,0.0003580137,0.0008771169,0.0001441122,0.0007939681,0.00001032371],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992168,0.002707773,0.0002820335,0.0003081477,0.000211882,0.001259537,0.0008673493,0.00007306199,0.002122201],"genre_scores_gemma":[0.989375,0.002592165,0.001191754,0.0007685953,0.0002810881,0.001347837,0.001157884,0.00002352137,0.003262123],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004682987,"threshold_uncertainty_score":0.01566613,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02555265505985911,"score_gpt":0.3412828668037834,"score_spread":0.3157302117439243,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}